AbbVie Inc vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? AbbVie Inc trades at $249.53 (market cap $438.19B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.58. The key difference: AbbVie Inc pays a 2.79% dividend while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF pays none, and AbbVie Inc is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | QDTY | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $263.58 | $46.71 |
52-Week Low | $197.38 | $36.57 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
QDTY trades at $39.78, up 1.02% today, with a bearish technical signal from moving averages and mixed oscillators. The stock shows consistent weekly dividend distributions, but key valuation and profitability ratios are unavailable. Recent news highlights ongoing dividend announcements from YieldMax ETFs, indicating a focus on income generation.
The outlook is cautious due to bearish technicals and lack of fundamental data; risks include market volatility and dependency on dividend strategy. Investors should seek updated financials for a clearer assessment of growth potential and sustainability.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →